SNDX · Syndax Pharmaceuticals Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Accounts activated (Tier 1+2 prescriber base) | 88% | 2Q26 | — |
| Cash, cash equivalents, and short- and long-term investments | $575.1M | As of June 30, 2026 | — |
| New patients on Niktimvo | 300 | 2Q26 | — |
| Niktimvo collaboration revenue | $18.1M | second quarter of 2026 | +93.4% |
|
|
|||
| Niktimvo infusions administered | 5,750 | 2Q26 | — |
| Niktimvo net revenue | $60.3M | second quarter of 2026 | — |
| Niktimvo net revenue (recorded by Incyte) | $60.3M | Second quarter 2026 | — |
| Niktimvo net revenue to INCY | $60.3M | 2Q26 | — |
| Patients treated commercially with Revuforj since launch | 1,630 | Since launch through 2Q26 | — |
| Revuforj net revenue | $54.7M | second quarter of 2026 | +91.3% |
|
|
|||
| Total prescriptions | 1,500 | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNDX
this stock
Syndax Pharmaceuticals Inc
|
$1.15B | -38.6% | +627.8% | — | 20.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.95B | +10.2% | +46.2% | 29.6 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +639.3% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +2.4% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$63.79B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNDX | -24.1% | -26.8% | -38.6% | -31.4% | -38.6% |
| SPY | -2.0% | +0.2% | +6.7% | +0.1% | +11.9% |
| vs SPY | -22.1% | -27.0% | -45.3% | -31.5% | -50.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.